REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
11.16
-0.44 (-3.79%)
At close: Jan 30, 2026, 4:00 PM EST
11.15
-0.01 (-0.09%)
After-hours: Jan 30, 2026, 7:53 PM EST
REGENXBIO Revenue
REGENXBIO had revenue of $29.73M in the quarter ending September 30, 2025, with 22.88% growth. This brings the company's revenue in the last twelve months to $161.32M, up 91.30% year-over-year. In the year 2024, REGENXBIO had annual revenue of $83.33M, down -7.66%.
Revenue (ttm)
$161.32M
Revenue Growth
+91.30%
P/S Ratio
3.55
Revenue / Employee
$456,992
Employees
353
Market Cap
564.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 246.72M |
| CorMedix | 214.30M |
| Gossamer Bio | 44.05M |
| Evommune | 13.00M |
| ProKidney | 744.00K |
| Altimmune | 20.00K |
RGNX News
- 2 days ago - Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action - PRNewsWire
- 4 days ago - FDA Clinical Hold Knocks REGENXBIO Stock - Benzinga
- 4 days ago - US FDA places clinical hold on Regenxbio's gene therapy trials - Reuters
- 4 days ago - REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs - PRNewsWire
- 5 days ago - REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away - Seeking Alpha
- 17 days ago - REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 20 days ago - REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program - PRNewsWire
- 6 weeks ago - REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire